Search research articles
Contact Us
Filters
Showing results (31-40 of 136) with videos related to
Page
of 14
Sort By:
Nature Reviews. Clinical Oncology
|
July 28, 2025
Clarifying the role of SONIA: supporting academic evidence on CDK4/6 inhibitor timing
Avi Petroff, Ian F Tannock, Daniel A Goldstein
Parkinsonism & Related Disorders
|
June 16, 2018
"Reversible Parkinsonism" following glyphosate exposure
Daniel A Goldstein, S Eliza Dunn, Katherine Karberg
Oncology (Williston Park, N.Y.)
|
March 19, 2015
Costs and effectiveness of genomic testing in the management of colorectal cancer
Daniel A Goldstein, Walid L Shaib, Christopher R Flowers
JAMA Oncology
|
June 21, 2019
Interventional Pharmacoeconomics-A New Discipline for a Cost-Constrained Environment
Mark J Ratain, Daniel A Goldstein, Allen S Lichter
The Lancet. Oncology
|
October 30, 2025
Subcutaneous immunotherapy-a wolf in sheep's clothing?
Roni Levin, Amol Akhade, Manju Sengar, et al.
JAMA Oncology
|
March 12, 2016
Perspectives in Oncology Drug Pricing-Reply
Daniel A Goldstein, David H Howard, Christopher R Flowers
Expert Review of Pharmacoeconomics & Outcomes Research
|
November 10, 2016
Economics of ramucirumab for metastatic colorectal cancer
Simon B Zeichner, Christine G Kohn, Daniel A Goldstein
JAMA Oncology
|
May 28, 2020
Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19
Daniel A Goldstein, Mark J Ratain, Leonard B Saltz
Cost Effectiveness and Resource Allocation : C/E
|
March 15, 2019
Cost effectiveness and affordability of trastuzumab in sub-Saharan Africa for early stage <i>HER2</i>-positive breast cancer
Noga Gershon, Yakir Berchenko, Peter S Hall, et al.
Reproductive Toxicology (Elmsford, N.Y.)
|
November 15, 2011
Comment: Aris and Leblanc "Maternal and fetal exposure to pesticides associated to genetically modified foods in Eastern Townships of Quebec, Canada"
Daniel A Goldstein, Samuel Dubelman, David Grothaus, et al.
Page
of 14
Search research articles
Search
Showing results (31-40 of 136) with videos related to
Sort By:
Page
of 14
Nature Reviews. Clinical Oncology
|
July 28, 2025
Clarifying the role of SONIA: supporting academic evidence on CDK4/6 inhibitor timing
Avi Petroff, Ian F Tannock, Daniel A Goldstein
Parkinsonism & Related Disorders
|
June 16, 2018
"Reversible Parkinsonism" following glyphosate exposure
Daniel A Goldstein, S Eliza Dunn, Katherine Karberg
Oncology (Williston Park, N.Y.)
|
March 19, 2015
Costs and effectiveness of genomic testing in the management of colorectal cancer
Daniel A Goldstein, Walid L Shaib, Christopher R Flowers
JAMA Oncology
|
June 21, 2019
Interventional Pharmacoeconomics-A New Discipline for a Cost-Constrained Environment
Mark J Ratain, Daniel A Goldstein, Allen S Lichter
The Lancet. Oncology
|
October 30, 2025
Subcutaneous immunotherapy-a wolf in sheep's clothing?
Roni Levin, Amol Akhade, Manju Sengar, et al.
JAMA Oncology
|
March 12, 2016
Perspectives in Oncology Drug Pricing-Reply
Daniel A Goldstein, David H Howard, Christopher R Flowers
Expert Review of Pharmacoeconomics & Outcomes Research
|
November 10, 2016
Economics of ramucirumab for metastatic colorectal cancer
Simon B Zeichner, Christine G Kohn, Daniel A Goldstein
JAMA Oncology
|
May 28, 2020
Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19
Daniel A Goldstein, Mark J Ratain, Leonard B Saltz
Cost Effectiveness and Resource Allocation : C/E
|
March 15, 2019
Cost effectiveness and affordability of trastuzumab in sub-Saharan Africa for early stage <i>HER2</i>-positive breast cancer
Noga Gershon, Yakir Berchenko, Peter S Hall, et al.
Reproductive Toxicology (Elmsford, N.Y.)
|
November 15, 2011
Comment: Aris and Leblanc "Maternal and fetal exposure to pesticides associated to genetically modified foods in Eastern Townships of Quebec, Canada"
Daniel A Goldstein, Samuel Dubelman, David Grothaus, et al.
Page
of 14